This inventor holds 1 USPTO granted patent. Top assignee: Fudan University. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Innovations of Inventor Tong Niu
Introduction
Tong Niu is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of inflammatory bowel diseases. His work is characterized by a focus on innovative compounds that have the potential to improve patient outcomes.
Latest Patents
Tong Niu holds a patent for a furaneone glycoside compound, which includes a pharmaceutical composition, preparation method, and application. This patent discloses a compound represented by formula A-1, along with its pharmaceutically acceptable salts and crystal forms. The pharmaceutical composition comprises the compound and a pharmaceutical adjuvant. The application of this compound is particularly relevant in the preparation of drugs aimed at treating inflammatory bowel diseases, especially ulcerative colitis. The furaneone glycoside compound has demonstrated a good effect in treating these conditions.
Career Highlights
Tong Niu is affiliated with Fudan University, where he engages in research and development in the pharmaceutical field. His work has garnered attention for its potential impact on healthcare and treatment methodologies.
Collaborations
Some of his notable coworkers include Jun Chang and Lin Jin, who contribute to the collaborative efforts in research and innovation at Fudan University.
Conclusion
Tong Niu's innovative work in developing pharmaceutical compounds showcases his commitment to advancing medical science. His contributions are vital in the ongoing efforts to improve treatments for inflammatory bowel diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
